Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer

  • Gautam Sethi
  • Bokyung Sung
  • Bharat B. Aggarwal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


Vascular endothelial growth inhibitor (VEGI, TNFSF-15) is a novel member of the tumor necrosis factor (TNF) superfamily that consists of 174 amino acids and exhibits a 20% to 30% sequence homology to other members of the TNF superfamily. The VEGI gene is expressed as a transmembrane protein predominantly in endothelial cells and induced generally in response to inflammatory stimuli. It mediates most of its cellular responses through the interaction of the death receptor-3. VEGI activates multiple cell signaling pathways including NF-κB, STAT3, JNK, p38 MAPK and p42/p44 MAPK. VEGI suppresses the proliferation of endothelial cells and tumor cells, induces maturation of dendritic cells and induces osteoclastogenesis. How VEGI mediates its effects in autoimmune diseases and tumorigenesis is the focus of this review.


Human Umbilical Vein Endothelial Cell Tumor Necrosis Factor Family Vascular Endothelial Growth Inhibitor Tumor Necrosis Factor Superfamily Intestinal Lamina Propria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76:959–962.PubMedCrossRefGoogle Scholar
  2. 2.
    Aggarwal BB. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745–756.PubMedCrossRefGoogle Scholar
  3. 3.
    Pitti RM, Marsters SA, Ruppert S et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687–12690.PubMedCrossRefGoogle Scholar
  4. 4.
    Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T-cells. J Biol Chem 1997; 272:25190–25194.PubMedCrossRefGoogle Scholar
  5. 5.
    Chicheportiche Y, Bourdon PR, Xu H et al. APRIL TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401–32410.PubMedCrossRefGoogle Scholar
  6. 6.
    Hahne M, Kataoka T, Schroter M et al. A new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188:1185–1190.PubMedCrossRefGoogle Scholar
  7. 7.
    Mauri DN, Ebner R, Montgomery RI et al. LIGHT, a new member of the TNF superfamily and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8:21–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Mukhopadhyay A, Ni J, Zhai Y et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274:15978–15981.PubMedCrossRefGoogle Scholar
  9. 9.
    Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 2003; 23:317–332.PubMedCrossRefGoogle Scholar
  10. 10.
    Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6:203–208.PubMedCrossRefGoogle Scholar
  11. 11.
    Westwick JK, Weitzel C, Minden A et al. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem 1994; 269:26396–26401.PubMedGoogle Scholar
  12. 12.
    Darnay BG, Aggarwal BB. Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol 1997; 61:559–566.PubMedGoogle Scholar
  13. 13.
    Tan KB, Harrop J, Reddy M et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells. Gene 1997; 204:35–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Yue TL, Ni J, Romanic AM et al. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999; 274:1479–1486.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhai Y, Ni J, Jiang GW et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999; 13:181–189.PubMedGoogle Scholar
  16. 16.
    Chew LJ, Pan H, Yu J et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 2002; 16:742–744.PubMedGoogle Scholar
  17. 17.
    Migone TS, Zhang J, Luo X et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T-cell costimulator. Immunity 2002; 16:479–492.PubMedCrossRefGoogle Scholar
  18. 18.
    Haridas V, Shrivastava A, Su J et al. VEGI, a new member of the TNF family activates nuclear factor-kappaB and c-Jun N-terminal kinase and modulates cell growth. Oncogene 1999; 18:6496–6504.PubMedCrossRefGoogle Scholar
  19. 19.
    Yu J, Tian S, Metheny-Barlow L et al. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 2001; 89:1161–1167.PubMedCrossRefGoogle Scholar
  20. 20.
    Wen L, Zhuang L, Luo X et al. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 2003; 278:39251–39258.PubMedCrossRefGoogle Scholar
  21. 21.
    Metheny-Barlow LJ, Li LY. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Semin Opthalmol 2006; 21:49–58.CrossRefGoogle Scholar
  22. 22.
    Papadakis KA, Prehn JL, Landers C et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T-cells and NK cells. J Immunol 2004; 172:7002–7007.PubMedGoogle Scholar
  23. 23.
    Kim MY, Toellner KM, White A et al. Neonatal and adult CD4+CD3-cells share similar gene expression profile and neonatal cells up-regulate OX40 ligand in response to TL1A (TNFSF15). J Immunol 2006; 177:3074–3081.PubMedGoogle Scholar
  24. 24.
    Prehn JL, Thomas LS, Landers CJ et al. The T-cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 2007; 178:4033–4038.PubMedGoogle Scholar
  25. 25.
    Tian F, Grimaldo S, Fugita M et al. The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 2007; 179:3742–3751.PubMedGoogle Scholar
  26. 26.
    Picornell Y, Mei L, Taylor K et al. TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis 2007.Google Scholar
  27. 27.
    Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005; 115:286–294.PubMedCrossRefGoogle Scholar
  28. 28.
    Young HA, Tovey MG. TL1A: a mediator of gut inflammation. Proc Natl Acad Sci USA 2006; 103:8303–8304.PubMedCrossRefGoogle Scholar
  29. 29.
    Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn’s disease Immunol Rev 2005; 206:277–295.PubMedCrossRefGoogle Scholar
  30. 30.
    Bamias G, Martin C, Marini 3rd M et al. Expression, localization and functional activity of TL1A, a novel Th 1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003; 171:4868–4874.PubMedGoogle Scholar
  31. 31.
    Prehn JL, Mehdizadeh S, Landers CJ et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 2004; 112:66–77.PubMedCrossRefGoogle Scholar
  32. 32.
    Yamazaki K, McGovern D, Ragoussis J et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. Hum Mol Genet 2005; 14:3499–3506.PubMedCrossRefGoogle Scholar
  33. 33.
    Bamias G, Mishina M, Nyce M et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 2006; 103:8441–8446.PubMedCrossRefGoogle Scholar
  34. 34.
    Cassatella MA, Pereira-da-Silva G, Tinazzi I et al. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 2007; 178:7325–7333.PubMedGoogle Scholar
  35. 35.
    Yang CR, Wang JH, Hsieh SL et al. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004; 11Suppl 1:S97–107.CrossRefGoogle Scholar
  36. 36.
    Tang CH, Hsu TL, Lin WW et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem 2007; 282:2346–2354.PubMedCrossRefGoogle Scholar
  37. 37.
    Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994; 56:423–435.PubMedGoogle Scholar
  38. 38.
    Frater-Schroder M, Risau W, Hallmann R et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84:5277–5281.PubMedCrossRefGoogle Scholar
  39. 39.
    Patterson C, Perrella MA, Endege WO et al. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 1996; 98:490–496.PubMedCrossRefGoogle Scholar
  40. 40.
    Wright P, Braun R, Babiuk L et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14:49–57.PubMedCrossRefGoogle Scholar
  41. 41.
    Yang CR, Hsieh SL, Teng CM et al. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004; 64:1122–1129.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhai Y, Yu J, Iruela-Arispe L et al. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 1999; 82:131–136.PubMedCrossRefGoogle Scholar
  43. 43.
    Pan X, Wang Y, Zhang M et al. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 2004; 10:1409–1414.PubMedGoogle Scholar
  44. 44.
    Hou W, Medynski D, Wu S et al. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 2005; 11:5595–5602.PubMedCrossRefGoogle Scholar
  45. 45.
    Parr C, Gan CH, Watkins G et al. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 2006; 9:73–81.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Gautam Sethi
    • 1
  • Bokyung Sung
    • 1
  • Bharat B. Aggarwal
    • 1
  1. 1.Cytokine Research Laboratory, Department of Experimental TherapeuticsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations